This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mitchell, B. M. Articles by Webb, R. C. Search for Related Content PubMed PubMed Citation Articles by Mitchell, B. M. Articles by Webb, R. C. Social Bookmarking                         What's this?

Impaired Vasodilation and Nitric Oxide Synthase Activity in Glucocorticoid-Induced Hypertension

R. Clinton Webb, PhD

Department of Physiology at the Medical College of Georgia, Augusta, GA 30912-3000; phone: (706) 721-7742; fax: (706) 721-7299cwebb{at}mcg.edu

Synthetic glucocorticoids are among the most widely prescribed medications by physicians. Although they have a vast array of beneficial effects such as immunosuppression and anti-inflammation, excess glucocorticoids can lead to iatrogenic Cushing’s syndrome, which includes hypertension and cardiovascular disease. The exact mechanism by which glucocorticoids elevate blood pressure is not completely understood, but it appears to be a complex pathology that involves increased responsiveness to vasoconstrictors and decreased vasodilator production. Nitric oxide is a vasodilator that plays a key role in blood pressure regulation, and previous studies have shown that a reduction in nitric oxide production or bioavailability contributes to hypertension. Tetrahydrobiopterin, a necessary cofactor for nitric oxide synthase activity, can affect nitric oxide production and bioavailability, with low levels causing decreased nitric oxide production. However, little is known about the interaction between glucocorticoids and tetrahydrobiopterin levels. In this review, the roles of nitric oxide and tetrahydrobiopterin in the pathogenesis of glucocorticoid hypertension will be discussed. Furthermore, the authors propose that glucocorticoids exert a genomic effect to decrease guanosine triphosphate cyclohydrolase I, the rate-limiting enzyme in the production of tetrahydrobiopterin. In the future, tetrahydrobiopterin supplementation in patients with iatrogenic Cushing’s syndrome may prove to be beneficial and decrease mortality attributed to cardiovascular disease.

Key Words: glucocorticoids • hypertension • Cushing’s syndrome • nitric oxide • tetrahydrobiopterin • vascular reactivity

Biological Research For Nursing, Vol. 4, No. 1, 16-21 (2002)
DOI: 10.1177/1099800402004001003


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Anagnostis, V. G. Athyros, K. Tziomalos, A. Karagiannis, and D. P. Mikhailidis The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2692 - 2701. [Abstract] [Full Text] [PDF]

				C. C. Chung, L. Shimmin, S. Natarajan, C. L. Hanis, E. Boerwinkle, and J. E. Hixson Glucocorticoid Receptor Gene Variant in the 3' Untranslated Region Is Associated with Multiple Measures of Blood Pressure J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 268 - 276. [Abstract] [Full Text] [PDF]

				A. L. Moens and D. A. Kass Tetrahydrobiopterin and Cardiovascular Disease Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2439 - 2444. [Abstract] [Full Text] [PDF]

				S. A. Summers and D. H. Nelson A Role for Sphingolipids in Producing the Common Features of Type 2 Diabetes, Metabolic Syndrome X, and Cushing's Syndrome Diabetes, March 1, 2005; 54(3): 591 - 602. [Abstract] [Full Text] [PDF]